Incidence, Management, Immediate and Long-Term Outcome of Guidewire and Device Related Grade III Coronary Perforations (from G3CAP - Cardiogroup VI Registry).


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
15 03 2021
Historique:
received: 01 09 2020
revised: 22 11 2020
accepted: 01 12 2020
pubmed: 3 1 2021
medline: 7 4 2021
entrez: 2 1 2021
Statut: ppublish

Résumé

Ellis grade III coronary artery perforations (G3-CAP) remain a life-threatening complication of percutaneous coronary intervention (PCI), with high morbidity and mortality and lack of consensus regarding optimal treatment strategies. We reviewed all PCIs performed in 10 European centers from 1993 to 2019 recording all G3-CAP along with management strategies, in-hospital and long-term outcome according to Device-related perforations (DP) and Guidewire-related perforations (WP). Among 106,592 PCI (including 7,773 chronic total occlusions), G3-CAP occurred in 311 patients (0.29%). DP occurred in 194 cases (62.4%), more commonly in proximal segments (73.2%) and frequently secondary to balloon dilatation (66.0%). WP arose in 117 patients (37.6%) with chronic total occlusions guidewires involved in 61.3% of cases. Overall sealing success rate was 90.7% and usually required multiple maneuvers (80.4%). The most commonly adopted strategies to obtain hemostasis were prolonged balloon inflation (73.2%) with covered stent implantation (64.4%) in the DP group, and prolonged balloon inflation (53.8%) with coil embolization (41%) in the WP group.  Procedural or in-hospital events arose in 38.2% of cases: mortality was higher after DP (7.2% vs 2.6%, p = 0.05) and acute stent thrombosis 3-fold higher (3.1% vs 0.9%, p = 0.19). At clinical follow-up, median 2 years, a major cardiovascular event occurred in one-third of cases (all-cause mortality 8.2% and 7.1% respectively, without differences between groups). In conclusion, although rare and despite improved rates of adequate perforation sealing G3-CAP cause significant adverse events. DP and WP result in different patterns of G3-CAP and management strategies should be based on this classification.

Identifiants

pubmed: 33387472
pii: S0002-9149(20)31369-2
doi: 10.1016/j.amjcard.2020.12.041
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

37-45

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Enrico Cerrato (E)

Interventional Cardiology Unit, San Luigi Gonzaga University Hospital (Orbassano) and Rivoli Infermi Hospital (Rivoli), Turin, Italy; Montefiore Medical Center, New York, New York. Electronic address: enrico.cerrato@gmail.com.

Marco Pavani (M)

Cardiology Unit, Santissima Annunziata Hospital, ASL CN1, Savigliano (CN), Italy.

Umberto Barbero (U)

Cardiology Unit, Santissima Annunziata Hospital, ASL CN1, Savigliano (CN), Italy.

Francesco Colombo (F)

Division of Cardiology, San Giovanni Bosco Hospital, Turin, Italy.

Antonio Mangieri (A)

Interventional Cardiology Unit, San Raffaele Hospital, Milan, Italy.

Nicola Ryan (N)

Department of Cardiology, Aberdeen Royal Infirmary, Aberdeen, Scotland.

Giorgio Quadri (G)

Interventional Cardiology Unit, San Luigi Gonzaga University Hospital (Orbassano) and Rivoli Infermi Hospital (Rivoli), Turin, Italy.

Francesco Tomassini (F)

Interventional Cardiology Unit, San Luigi Gonzaga University Hospital (Orbassano) and Rivoli Infermi Hospital (Rivoli), Turin, Italy.

Davide Giacomo Presutti (DG)

Cardiology Unit, Valduce Hospital, Como, Italy.

Simone Calcagno (S)

Department of Clinical Internal, Anesthesiological and Cardiovascular Science, Sapienza University of Rome, Rome, Italy.

Alfonso Franzè (A)

Interventional Cardiology Unit, San Luigi Gonzaga University Hospital (Orbassano) and Rivoli Infermi Hospital (Rivoli), Turin, Italy.

Barbara Bellini (B)

Interventional Cardiology Unit, San Raffaele Hospital, Milan, Italy.

Fabrizio D'Ascenzo (F)

Division of Cardiology, Città della Salute e della Scienza di Torino, Turin, Italy; Montefiore Medical Center, New York, New York.

Alfonso Ielasi (A)

Clinical and Interventional Cardiology Unit, Sant'Ambrogio Cardio-Thoracic Center, Milan, Italy.

Michele De Benedictis (M)

Cardiology Unit, Santissima Annunziata Hospital, ASL CN1, Savigliano (CN), Italy.

Lorenzo Azzalini (L)

Division of Cardiology, VCU Health Pauley Heart Center and Virginia Commonwealth University, Richmond, Virginia.

Massimo Mancone (M)

Department of Clinical Internal, Anesthesiological and Cardiovascular Science, Sapienza University of Rome, Rome, Italy.

Javier Escaned (J)

Hospital Clinico San Carlos IDISSC, Complutense University of Madrid, Madrid, Spain.

Matteo Montorfano (M)

Interventional Cardiology Unit, San Raffaele Hospital, Milan, Italy.

Azeem Latib (A)

Montefiore Medical Center, New York, New York.

Ferdinando Varbella (F)

Interventional Cardiology Unit, San Luigi Gonzaga University Hospital (Orbassano) and Rivoli Infermi Hospital (Rivoli), Turin, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH